Compare iShares Core Growth Allocation ETF (AOR) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Nuvalent Inc — how do they compare? iShares Core Growth Allocation ETF trades at $68.84, while Nuvalent Inc trades at $123.95 (market cap $9.80B). The key difference: Nuvalent Inc is trading nearer its 52-week high, iShares Core Growth Allocation ETF nearer its low. Which is the better fit depends on your goals.
| AOR | NUVL | |
|---|---|---|
52-Week High | $69.85 | $123.90 |
52-Week Low | $61.00 | $72.16 |
Market Cap | — | $9.80B |
Sector | — | Technology |
Enterprise Value | — | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares Core Growth Allocation ETF (AOR) trades at $69.10, up 0.25% on the day, with a bearish technical signal from moving averages and neutral oscillators. The fund maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low 0.20% expense ratio. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.
Outlook: AOR offers diversified, low-cost exposure but faces headwinds from equity-bond correlation shifts. Risks include interest rate sensitivity and competition from pure equity funds. Analyst sentiment is mixed, balancing simplicity against relative returns.
Nuvalent (NUVL) trades at $123.9, up 0.06% on the day, following GSK's $10.6 billion all-cash acquisition offer at $124 per share announced on June 9, 2026 (Reuters). The stock is near the acquisition price, with bullish technical signals from moving averages but overbought RSI readings. Financially, the company reports negative earnings and cash flow from operations, with a P/B ratio of 8.35. Recent news highlights multiple law firms investigating the fairness of the deal.
The acquisition by GSK provides a clear exit near current levels, limiting upside but reducing volatility. Key risks include deal completion uncertainty and shareholder litigation. Analyst sentiment is mixed with 42% buy ratings. Investors should weigh the guaranteed offer against fundamental weaknesses and legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
